<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368926</url>
  </required_header>
  <id_info>
    <org_study_id>BP25713</org_study_id>
    <nct_id>NCT01368926</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics, Safety and Tolerability of RO4917523 Conducted in 2 Phases: a Single-Dose, Cross-Over Administration to Healthy Japanese Subjects and a Multiple-Dose Administration to Healthy Japanese and Caucasian Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This double-blind, randomized, placebo-controlled, 2-Part study will evaluate the
      pharmacokinetics and safety of RO4917523 in healthy Japanese and Caucasian volunteers. In
      Part 1, healthy Japanese volunteers will be randomized to receive 2 oral doses of either
      RO4917523 or placebo, with a washout period of 21 days between dosing. In Part 2, healthy
      Japanese and Caucasian volunteers will be randomized in cohorts to receive either RO4917523
      or placebo orally daily for 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Pharmacokinetics: Area under the concentration - time curve (AUC) (single/multiple oral dose in healthy Japanese subjects)</measure>
    <time_frame>approximately 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Comparison of pharmacokinetics (area under the concentration - time curve [AUC]) between healthy Caucasian and Japanese subjects after 14 days of daily oral dosing</measure>
    <time_frame>approximately 9 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events in Japanese an Caucasian subjects</measure>
    <time_frame>approximately 21 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4917523</intervention_name>
    <description>single oral doses</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4917523</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral doses</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese (Part 1 + 2) or Caucasian (Part 2) adults, 18- 50 years of age

          -  Japanese subjects must have Japanese parents and grandparents who were born in Japan

          -  Caucasian subjects must have 4 Caucasian grandparents

          -  Body mass index (BMI) 18.5 to 26 kg/m2, and a body weight of at least 45 kg

          -  Non-smoker for at least 90 days prior to dosing Day 1

        Exclusion Criteria:

          -  Participation in a clinical trial with an investigational drug within 90 days prior to
             dosing Day 1. (Volunteers having participated in Part 1 will not be allowed to
             participate in Part 2 and vice versa)

          -  History or evidence of any clinically significant disease or disorder

          -  Pregnant or lactating women

          -  Positive for hepatitis B, hepatitis C or HIV

          -  Positive drug screen test, positive cotinine test and/or positive alcohol test

          -  Any confirmed significant allergic reactions to any drug, or multiple allergies in the
             judgement of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

